CD164 and glioma: Additionally, we found that elevated CD164 expression was strongly associated with poorer prognosis in eight tumor types, including glioblastoma, lower grade glioma, acute myeloid leukemia from the TARGET dataset, breast cancer, liver hepatocellular carcinoma, acute myeloid leukemia, and pancreatic cancer (Figure 1B), emphasizing its potential as a prognostic marker and therapeutic target in various cancers.